Utilization of MiRNAs As Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 9

PMID 39519256

Authors

Alexandros Lazaridis

Hector Katifelis

Emmanouil Kalampokas

Dimitra Lambropoulou

Gerasimos Aravantinos

Maria Gazouli

Nikos F Vlahos

Affiliations

Soon will be listed here.

Abstract

Gynecological cancer is a term referring to malignancies that typically involve ovarian, cervical, uterine, vaginal, and vulvar cancer. Combined, these cancers represent major causes of morbidity and mortality in women with a heavy socioeconomic impact. MiRNAs are small non-coding RNAs that are intensively studied in the field of cancer and changes in them have been linked to a variety of processes involved in cancer that range from tumorigenesis to prognosis and metastatic potential. This review aims to summarize the existing literature that has linked miRNAs with each of the female malignancies as potential biomarkers in diagnosis (circulating miRNAs), in tumor histology and prognosis (as tissue biomarkers), and for local (lymph node) and distant metastatic disease.

References

Gocze K, Gombos K, Kovacs K, Juhasz K, Gocze P, Kiss I . MicroRNA expressions in HPV-induced cervical dysplasia and cancer. Anticancer Res. 2015; 35(1):523-30. View

Sharma P, Gupta A . MicroRNAs: potential biomarkers for diagnosis and prognosis of different cancers. Transl Cancer Res. 2022; 9(9):5798-5818. PMC: 8798648. DOI: 10.21037/tcr-20-1294. View

Liu Y, Zhang Y, Xiao B, Tang N, Hu J, Liang S . MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma. Cell Death Dis. 2021; 12(6):618. PMC: 8206076. DOI: 10.1038/s41419-021-03905-3. View

Chen Z, Guo X, Sun S, Lu C, Wang L . Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses. Bioengineered. 2020; 11(1):311-317. PMC: 7161537. DOI: 10.1080/21655979.2020.1736755. View

Benati M, Montagnana M, Danese E, Paviati E, Giudici S, Franchi M . Evaluation of mir-203 Expression Levels and DNA Promoter Methylation Status in Serum of Patients with Endometrial Cancer. Clin Lab. 2017; 63(10):1675-1681. DOI: 10.7754/Clin.Lab.2017.170421. View

Ren X, Zhang H, Cong H, Wang X, Ni H, Shen X . Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Pathol Oncol Res. 2018; 24(4):739-744. DOI: 10.1007/s12253-018-0392-x. View

Nascimento N, Gally T, Borges G, Campos L, Kaneto C . Systematic review of circulating MICRORNAS as biomarkers of cervical carcinogenesis. BMC Cancer. 2022; 22(1):862. PMC: 9357301. DOI: 10.1186/s12885-022-09936-z. View

Wei H, Tang Q, Zhang K, Sun J, Ding R . miR-532-5p is a prognostic marker and suppresses cells proliferation and invasion by targeting TWIST1 in epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 2018; 22(18):5842-5850. DOI: 10.26355/eurrev_201809_15911. View

Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G, Naccarati A . MicroRNAs as markers of progression in cervical cancer: a systematic review. BMC Cancer. 2018; 18(1):696. PMC: 6020348. DOI: 10.1186/s12885-018-4590-4. View

10.

Niemira M, Erol A, Bielska A, Zeller A, Skwarska A, Chwialkowska K . Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer. Sci Rep. 2023; 13(1):19287. PMC: 10630404. DOI: 10.1038/s41598-023-45317-7. View

11.

Cheung T, Man K, Yu M, Yim S, Siu N, Lo K . Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle. 2012; 11(15):2876-84. DOI: 10.4161/cc.21278. View

12.

Peng D, Luo M, Qiu L, He Y, Wang X . Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012; 27(4):1238-44. PMC: 3583406. DOI: 10.3892/or.2012.1625. View

13.

Peng C, Yue L, Zhou Y, Tang S, Kan C, Xia L . miR-100-3p inhibits cell proliferation and induces apoptosis in human gastric cancer through targeting to BMPR2. Cancer Cell Int. 2020; 19:354. PMC: 6935118. DOI: 10.1186/s12935-019-1060-2. View

14.

Hang J, Wei F, Yan Z, Zhang X, Xu K, Zhu Y . The value of miR-510 in the prognosis and development of colon cancer. Open Med (Wars). 2021; 16(1):795-804. PMC: 8126670. DOI: 10.1515/med-2021-0251. View

15.

Oliveira D, Carlsen A, Heegaard N, Prahm K, Christensen I, Hogdall C . Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass. PLoS One. 2019; 14(11):e0225249. PMC: 6860451. DOI: 10.1371/journal.pone.0225249. View

16.

Dolivet E, Gaichies L, Jeanne C, Bazille C, Briand M, Vernon M . Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors. Int J Mol Sci. 2023; 24(21). PMC: 10649586. DOI: 10.3390/ijms242116016. View

17.

Favero A, Segatto I, Perin T, Belletti B . The many facets of miR-223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response. Wiley Interdiscip Rev RNA. 2021; 12(6):e1659. PMC: 8518860. DOI: 10.1002/wrna.1659. View

18.

Cohn D, Fabbri M, Valeri N, Alder H, Ivanov I, Liu C . Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol. 2010; 202(6):656.e1-8. PMC: 4278076. DOI: 10.1016/j.ajog.2010.02.051. View

19.

Gheni N, Westenberg D . Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings. Indian J Pathol Microbiol. 2020; 63(Supplement):S123-S128. DOI: 10.4103/IJPM.IJPM_136_19. View

20.

De Decker K, Wenzel H, Bart J, van der Aa M, Kruitwagen R, Nijman H . Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study. Acta Obstet Gynecol Scand. 2023; 102(3):246-256. PMC: 9951382. DOI: 10.1111/aogs.14518. View